ArticleFrontiers in pharmacology2026
Recurrent and persistent refractive errors after restarting isotretinoin treatment: a case report.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Isotretinoin is a vitamin A derivative widely used for moderate-to-severe acne, and is known to cause multiple systemic and ocular adverse events. Refractive errors, such as myopia and astigmatism, are commonly considered reversible after discontinuation of isotretinoin treatment. However, the visual changes and subsequent prognosis after re-exposure to isotretinoin are rarely reported. Case Presentation: A 21-year-old male initiated oral isotretinoin at 10 mg twice daily for acne vulgaris. Twelve days later, the patient developed acute visual deterioration. The eye examination revealed mild myopic astigmatism in the right eye and mild myopia in the left eye. The patient's visual acuity returned to normal at approximately 20 days after isotretinoin cessation. Then, the patient later self-restarted isotretinoin (10 mg, twice daily) for 10 days, which again resulted in decreased visual acuity. Although the patient discontinued isotretinoin, the visual acuity did not recover to baseline over a 14-month follow-up period. The Naranjo Adverse Drug Reaction Probability Scale was eight points, indicating a "probable" causal relationship between isotretinoin and refractive error. Conclusion: Myopia and astigmatism might happen concurrently after isotretinoin administration. In addition, recurrent and persistent refractive errors might occur upon restarting isotretinoin in patients with prior history of isotretinoin-related ocular complications. Clinicians should consult patients to take extra precautions on isotretinoin medication when they have a history of ocular disease or ocular complications with isotretinoin administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.